382 related articles for article (PubMed ID: 35455461)
1. Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol-An All-Inclusive Guide for Clinicians.
Principe L; Lupia T; Andriani L; Campanile F; Carcione D; Corcione S; De Rosa FG; Luzzati R; Stroffolini G; Steyde M; Decorti G; Di Bella S
Pharmaceuticals (Basel); 2022 Apr; 15(4):. PubMed ID: 35455461
[TBL] [Abstract][Full Text] [Related]
2. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?
Le Terrier C; Freire S; Nordmann P; Poirel L
Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):339-354. PubMed ID: 38095831
[TBL] [Abstract][Full Text] [Related]
3. Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions.
Blanco-Martín T; Alonso-García I; González-Pinto L; Outeda-García M; Guijarro-Sánchez P; López-Hernández I; Pérez-Vázquez M; Aracil B; López-Cerero L; Fraile-Ribot P; Oliver A; Vázquez-Ucha JC; Beceiro A; Bou G; Arca-Suárez J;
Int J Antimicrob Agents; 2024 May; 63(5):107150. PubMed ID: 38513748
[TBL] [Abstract][Full Text] [Related]
4. Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of
Le Terrier C; Nordmann P; Buchs C; Poirel L
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0154823. PubMed ID: 38415988
[TBL] [Abstract][Full Text] [Related]
5. Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients.
Barbier F; Hraiech S; Kernéis S; Veluppillai N; Pajot O; Poissy J; Roux D; Zahar JR;
Ann Intensive Care; 2023 Jul; 13(1):65. PubMed ID: 37462830
[TBL] [Abstract][Full Text] [Related]
6. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan.
Kuo SC; Wang YC; Tan MC; Huang WC; Shiau YR; Wang HY; Lai JF; Huang IW; Lauderdale TL
J Antimicrob Chemother; 2021 Jul; 76(8):2071-2078. PubMed ID: 33956969
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
Sader HS; Castanheira M; Duncan LR; Mendes RE
Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales.
Danjean M; Hobson CA; Gits-Muselli M; Courroux C; Monjault A; Bonacorsi S; Birgy A
Clin Microbiol Infect; 2022 Nov; 28(11):1503.e1-1503.e3. PubMed ID: 35777602
[TBL] [Abstract][Full Text] [Related]
10. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens.
Bush K
Int J Antimicrob Agents; 2015 Nov; 46(5):483-93. PubMed ID: 26498989
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial and Diagnostic Stewardship of the Novel β-Lactam/β-Lactamase Inhibitors for Infections Due to Carbapenem-Resistant Enterobacterales Species and
Ferous S; Anastassopoulou C; Pitiriga V; Vrioni G; Tsakris A
Antibiotics (Basel); 2024 Mar; 13(3):. PubMed ID: 38534720
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors.
Gatti M; Pea F
Expert Rev Clin Pharmacol; 2021 May; 14(5):583-599. PubMed ID: 33687300
[TBL] [Abstract][Full Text] [Related]
13. Transcending the challenge of evolving resistance mechanisms in
Hujer AM; Marshall SH; Mack AR; Hujer KM; Bakthavatchalam YD; Umarkar K; Palwe SR; Takalkar S; Joshi PR; Shrivastava R; Periasamy H; Bhagwat SS; Patel MV; Veeraraghavan B; Bonomo RA
mBio; 2023 Oct; 14(6):e0111823. PubMed ID: 37889005
[TBL] [Abstract][Full Text] [Related]
14. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.
Meletiadis J; Paranos P; Georgiou PC; Vourli S; Antonopoulou S; Michelaki A; Vagiakou E; Pournaras S
Int J Antimicrob Agents; 2021 Nov; 58(5):106440. PubMed ID: 34551356
[TBL] [Abstract][Full Text] [Related]
15. Carbapenemase producing
Karaiskos I; Galani I; Papoutsaki V; Galani L; Giamarellou H
Expert Rev Anti Infect Ther; 2022 Jan; 20(1):53-69. PubMed ID: 34033499
[TBL] [Abstract][Full Text] [Related]
16. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
17. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
Bader MS; Loeb M; Leto D; Brooks AA
Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
[TBL] [Abstract][Full Text] [Related]
18. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?
Wright H; Bonomo RA; Paterson DL
Clin Microbiol Infect; 2017 Oct; 23(10):704-712. PubMed ID: 28893690
[TBL] [Abstract][Full Text] [Related]
19. Innovative β-lactam/β-lactamase inhibitor combinations for carbapenem-resistant Gram-negative bacteria.
Giacobbe DR; Bassetti M
Future Microbiol; 2022 Apr; 17():393-396. PubMed ID: 35234517
[No Abstract] [Full Text] [Related]
20. [New Antibiotics for Treatment of Highly Resistant Gram-negative Bacteria].
Probst-Kepper M; Geginat G
Anasthesiol Intensivmed Notfallmed Schmerzther; 2018 Jul; 53(7-08):529-542. PubMed ID: 30036899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
